PhotoagingNCT07879833
AI-Personalized Skincare Regimen for Facial Photoaging in Women
A study testing AI-personalized skin longevity regimen in people with Photoaging and Skin Aging, run by MDalgorithms Inc. at 1 site in United States.
Trial summary
The goal of this clinical study was to learn whether a skincare regimen personalized by an artificial intelligence (AI) skin-analysis tool improves signs of facial skin aging in women aged 35 to 65 with mild-to-moderate facial photoaging. Read more about this study
- Who is it for?
- Ages 35 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Photoaging, Skin Aging
- What is being tested?
- AI-personalized skin longevity regimen
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 43 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Sep 2025to 13 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- -
- Female, aged 35 to 65 years
- Fitzpatrick skin phototype II to VI
- Mild-to-moderate facial photoaging
- Willing to complete a 2-week washout from anti-aging products before baseline
- Able to provide written informed consent
Who cannot join
- Active facial dermatoses
- Use of prescription retinoids within 6 months before enrollment
- Cosmetic facial procedures within 3 months (injectables within 12 months) before enrollment
- Known allergy to any study product ingredient
- -
Trial locations and contacts
1 site in 1 country.
United States1 site
SGS North America Inc., Clinical Research
Richardson, Texas, 75081
About this study
Official title: A Clinical Study to Assess the Efficacy of a Customized Skincare Regimen on Women Exhibiting Signs of Skin Aging
The goal of this clinical study was to learn whether a skincare regimen personalized by an artificial intelligence (AI) skin-analysis tool improves signs of facial skin aging in women aged 35 to 65 with mild-to-moderate facial photoaging. The main questions it aimed to answer were: Does the personalized regimen improve fine lines, wrinkles, firmness, smoothness, tone and other signs of skin aging after 4 and 12 weeks of use? Is the regimen well tolerated? Participants completed an online skin questionnaire and uploaded a facial selfie, and the AI tool assigned one of three night creams. Each participant then used a personalized kit at home for 12 weeks: a vitamin C serum and SPF 30 sunscreen in the morning; the assigned night cream (0.3% retinol, 0.6% retinol, or bakuchiol, each with a triple-peptide complex), an eye cream, and a dark spot remover in the evening; and a daily oral marine collagen supplement. Participants visited the clinic at baseline, week 4 and week 12 for expert skin grading, skin measurements, photographs and questionnaires.
Read the detailed description
This was a 12-week, single-center, single-arm, subject-blinded study (Protocol C25-D123, version 1.0) conducted at SGS North America Inc. (Richardson, TX, USA) and approved by Sterling Institutional Review Board (IRB ID 14718) on September 26, 2025. Product labels were covered with opaque tape so participants were blinded to the ingredients and formulation assigned.
Personalization: Each participant completed an online questionnaire (skin concerns, sensitivities, environmental exposures and lifestyle) and uploaded a facial selfie that was analyzed by a proprietary AI system for wrinkle severity, pigmentation and texture. Based on this analysis, each participant was assigned one of three night creams: Cream A (0.3% retinol with the SenoP3 triple-peptide complex) for sensitive skin or early aging, Cream B (0.6% retinol with SenoP3) for moderate photoaging with established retinoid tolerance, or Cream C (bakuchiol with SenoP3) for retinoid-sensitive skin.
Regimen: Morning - 10% tetrahexyldecyl ascorbate vitamin C serum and SPF 30 sunscreen. Evening - assigned night cream, eye cream with SenoP3, and dark spot remover as needed. Daily - oral wild-caught marine collagen supplement (type I collagen peptides).
Assessments at baseline, week 4 and week 12: expert clinical grading on a modified Griffiths 10-point scale; standardized VISIA photography; PRIMOS 3D profilometry (roughness, wrinkle depth and volume at crow's feet, forehead and perioral areas); Corneometer (hydration), Tewameter (transepidermal water loss) and Indentometer (firmness) under controlled conditions; subject self-assessment questionnaires; and adverse event monitoring. Comparisons between night-cream subgroups were exploratory.
This study is being registered retrospectively after completion.
- Conditions
- Photoaging, Skin Aging
- Being tested
- AI-personalized skin longevity regimen
- Keywords
- artificial intelligence, personalized skin care, retinol, bakuchiol, peptides, marine collagen
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-personalized skin longevity regimenOther
Also called Nuvane AI-Powered Personalized Skin Longevity Kit
Multi-product topical and oral regimen used at home for 12 weeks, personalized by a proprietary AI analysis of an online questionnaire and facial selfie. Morning: 10% tetrahexyldecyl ascorbate vitamin C serum and SPF 30 sunscreen. Evening: AI-assigned night cream - Cream A (0.3% retinol), Cream B (0.6% retinol) or Cream C (bakuchiol), each with the SenoP3 triple-peptide complex (copper tripeptide-1, palmitoyl tripeptide-38, acetyl hexapeptide-8) - plus an eye cream with SenoP3 and a dark spot remover as needed. Daily: oral wild-caught marine collagen supplement (type I collagen peptides).
| Study group | Role | What they receive |
|---|---|---|
| AI-Personalized Skincare Regimen | Experimental | Women aged 35-65 with mild-to-moderate facial photoaging used an AI-personalized regimen at home for 12 weeks: vitamin C serum and SPF 30 sunscreen (morning); an AI-assigned night cream (0.3% retinol, 0.6% retinol, or bakuchiol, each with the SenoP3 triple-peptide complex), eye cream, and dark spot remover as needed (evening); and a daily oral marine collagen supplement. Receives: Other: AI-personalized skin longevity regimen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Expert-Graded Facial Photoaging Parameters (Modified Griffiths 10-Point Scale)
A trained expert grader assessed facial photoaging parameters (fine lines at the crow's feet and global face, wrinkles, firmness, elasticity, smoothness, tone evenness, radiance, dark circles, puffiness, pore appearance and overall condition) on a modified Griffiths 10-point analog scale (0 = none to 9 = severe; lower scores indicate better skin condition). Change from baseline is reported.
Measured: Baseline, Week 4 and Week 12
Secondary outcomes (6)
Change From Baseline in Skin Hydration (Corneometer)
Stratum corneum hydration measured with the Corneometer CM 825 (arbitrary units) under controlled conditions after acclimatization; higher values indicate better hydration.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Transepidermal Water Loss (Tewameter)
Skin barrier function measured as transepidermal water loss (g/m2/h) with the Tewameter TM 300/TM 330T under controlled conditions; lower values indicate better barrier function. Exploratory comparison between night-cream subgroups.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Skin Firmness (Indentometer)
Skin firmness measured with the Indentometer IDM 800 under controlled conditions.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Skin Surface Topography (PRIMOS 3D Profilometry)
Skin surface roughness (Ra), wrinkle depth (Rz) and wrinkle volume at the crow's feet, forehead and perioral areas measured by PRIMOS 3D optical profilometry.
Measured: Baseline, Week 4 and Week 12
Subject Self-Assessment of Skin Parameters
Percentage of participants reporting improvement on a 15-item self-assessment questionnaire developed for this study (five-point Likert scale), including overall satisfaction with the regimen.
Measured: Week 4 and Week 12
Number of Participants With Adverse Events
Tolerability assessed by recording adverse events, including product-related skin reactions, throughout the study.
Measured: Baseline through Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2026
- Study start30 Sep 2025
- Primary completion13 Feb 2026
- Study completion13 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for PhotoagingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All participants received the same multi-product regimen; the night cream formulation (0.3% retinol, 0.6% retinol, or bakuchiol, each with a triple-peptide complex) was assigned by an AI skin-analysis algorithm rather than randomized.
- Masking
- None (open label)
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- MDalgorithms Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Nana S Thompson, PhD, MPH, Principal investigator, SGS North America Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07879833
- Sponsor's protocol ID
- C25-D123
- Status last verified
- Oct 2026
- First submitted
- 10 Oct 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly shared to protect participant privacy. Aggregate data supporting published findings are available from the sponsor upon reasonable request.
Publications
Kafi R, Kwak HS, Schumacher WE, Cho S, Hanft VN, Hamilton TA, King AL, Neal JD, Varani J, Fisher GJ, Voorhees JJ, Kang S. Improvement of naturally aged skin with vitamin A (retinol). Arch Dermatol. 2007 May;143(5):606-12. doi: 10.1001/archderm.143.5.606.
PubMed 17515510Dhaliwal S, Rybak I, Ellis SR, Notay M, Trivedi M, Burney W, Vaughn AR, Nguyen M, Reiter P, Bosanac S, Yan H, Foolad N, Sivamani RK. Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing. Br J Dermatol. 2019 Feb;180(2):289-296. doi: 10.1111/bjd.16918. Epub 2018 Sep 21.
PubMed 29947134Griffiths CE, Wang TS, Hamilton TA, Voorhees JJ, Ellis CN. A photonumeric scale for the assessment of cutaneous photodamage. Arch Dermatol. 1992 Mar;128(3):347-51.
PubMed 1550366
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study to Assess the Efficacy of a Customized Skincare Regimen on Women Exhibiting Signs of Skin Aging
- ClinicalTrials.gov ID
- NCT07879833
- Acronym / sponsor ID
- C25-D123
- Conditions
- Photoaging, Skin Aging
- Keywords
- artificial intelligence, personalized skin care, retinol, bakuchiol, peptides, marine collagen
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 43 participants (actual)
- Lead sponsor
- MDalgorithms Inc.Industry (pharma, biotech, devices)
- Study start
- 30 Sep 2025 (actual)
- Primary completion
- 13 Feb 2026 (actual)
- Study completion
- 13 Feb 2026 (actual)
- First posted
- 19 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical study was to learn whether a skincare regimen personalized by an artificial intelligence (AI) skin-analysis tool improves signs of facial skin aging in women aged 35 to 65 with mild-to-moderate facial photoaging. The main questions it aimed to answer were: Does the personalized regimen improve fine lines, wrinkles, firmness, smoothness, tone and other signs of skin aging after 4 and 12 weeks of use? Is the regimen well tolerated? Participants completed an online skin questionnaire and uploaded a facial selfie, and the AI tool assigned one of three night creams. Each participant then used a personalized kit at home for 12 weeks: a vitamin C serum and SPF 30 sunscreen in the morning; the assigned night cream (0.3% retinol, 0.6% retinol, or bakuchiol, each with a triple-peptide complex), an eye cream, and a dark spot remover in the evening; and a daily oral marine collagen supplement. Participants visited the clinic at baseline, week 4 and week 12 for expert skin grading, skin measurements, photographs and questionnaires.
Detailed description
This was a 12-week, single-center, single-arm, subject-blinded study (Protocol C25-D123, version 1.0) conducted at SGS North America Inc. (Richardson, TX, USA) and approved by Sterling Institutional Review Board (IRB ID 14718) on September 26, 2025. Product labels were covered with opaque tape so participants were blinded to the ingredients and formulation assigned.
Personalization: Each participant completed an online questionnaire (skin concerns, sensitivities, environmental exposures and lifestyle) and uploaded a facial selfie that was analyzed by a proprietary AI system for wrinkle severity, pigmentation and texture. Based on this analysis, each participant was assigned one of three night creams: Cream A (0.3% retinol with the SenoP3 triple-peptide complex) for sensitive skin or early aging, Cream B (0.6% retinol with SenoP3) for moderate photoaging with established retinoid tolerance, or Cream C (bakuchiol with SenoP3) for retinoid-sensitive skin.
Regimen: Morning - 10% tetrahexyldecyl ascorbate vitamin C serum and SPF 30 sunscreen. Evening - assigned night cream, eye cream with SenoP3, and dark spot remover as needed. Daily - oral wild-caught marine collagen supplement (type I collagen peptides).
Assessments at baseline, week 4 and week 12: expert clinical grading on a modified Griffiths 10-point scale; standardized VISIA photography; PRIMOS 3D profilometry (roughness, wrinkle depth and volume at crow's feet, forehead and perioral areas); Corneometer (hydration), Tewameter (transepidermal water loss) and Indentometer (firmness) under controlled conditions; subject self-assessment questionnaires; and adverse event monitoring. Comparisons between night-cream subgroups were exploratory.
This study is being registered retrospectively after completion.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All participants received the same multi-product regimen; the night cream formulation (0.3% retinol, 0.6% retinol, or bakuchiol, each with a triple-peptide complex) was assigned by an AI skin-analysis algorithm rather than randomized.
| Arm | Type | Receives |
|---|---|---|
| AI-Personalized Skincare Regimen | Experimental | Other: AI-personalized skin longevity regimenWomen aged 35-65 with mild-to-moderate facial photoaging used an AI-personalized regimen at home for 12 weeks: vitamin C serum and SPF 30 sunscreen (morning); an AI-assigned night cream (0.3% retinol, 0.6% retinol, or bakuchiol, each with the SenoP3 triple-peptide complex), eye cream, and dark spot remover as needed (evening); and a daily oral marine collagen supplement. |
Who may qualify
- Ages
- 35 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- -
- Female, aged 35 to 65 years
- Fitzpatrick skin phototype II to VI
- Mild-to-moderate facial photoaging
- Willing to complete a 2-week washout from anti-aging products before baseline
Key exclusion criteria (5 listed)
- Active facial dermatoses
- Use of prescription retinoids within 6 months before enrollment
- Cosmetic facial procedures within 3 months (injectables within 12 months) before enrollment
- Known allergy to any study product ingredient
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-personalized skin longevity regimenAlso: Nuvane AI-Powered Personalized Skin Longevity KitMulti-product topical and oral regimen used at home for 12 weeks, personalized by a proprietary AI analysis of an online questionnaire and facial selfie. Morning: 10% tetrahexyldecyl ascorbate vitamin C serum and SPF 30 sunscreen. Evening: AI-assigned night cream - Cream A (0.3% retinol), Cream B (0.6% retinol) or Cream C (bakuchiol), each with the SenoP3 triple-peptide complex (copper tripeptide-1, palmitoyl tripeptide-38, acetyl hexapeptide-8) - plus an eye cream with SenoP3 and a dark spot remover as needed. Daily: oral wild-caught marine collagen supplement (type I collagen peptides). | Other | AI-Personalized Skincare Regimen |
Primary outcome
Change From Baseline in Expert-Graded Facial Photoaging Parameters (Modified Griffiths 10-Point Scale)
Time frame: Baseline, Week 4 and Week 12
A trained expert grader assessed facial photoaging parameters (fine lines at the crow's feet and global face, wrinkles, firmness, elasticity, smoothness, tone evenness, radiance, dark circles, puffiness, pore appearance and overall condition) on a modified Griffiths 10-point analog scale (0 = none to 9 = severe; lower scores indicate better skin condition). Change from baseline is reported.
6 secondary outcomes
Change From Baseline in Skin Hydration (Corneometer)
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Transepidermal Water Loss (Tewameter)
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Skin Firmness (Indentometer)
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Skin Surface Topography (PRIMOS 3D Profilometry)
Time frame: Baseline, Week 4 and Week 12
Subject Self-Assessment of Skin Parameters
Time frame: Week 4 and Week 12
Number of Participants With Adverse Events
Time frame: Baseline through Week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Background: PubMed 17515510Kafi R, Kwak HS, Schumacher WE, Cho S, Hanft VN, Hamilton TA, King AL, Neal JD, Varani J, Fisher GJ, Voorhees JJ, Kang S. Improvement of naturally aged skin with vitamin A (retinol). Arch Dermatol. 2007 May;143(5):606-12. doi: 10.1001/archderm.143.5.606.
- Background: PubMed 29947134Dhaliwal S, Rybak I, Ellis SR, Notay M, Trivedi M, Burney W, Vaughn AR, Nguyen M, Reiter P, Bosanac S, Yan H, Foolad N, Sivamani RK. Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing. Br J Dermatol. 2019 Feb;180(2):289-296. doi: 10.1111/bjd.16918. Epub 2018 Sep 21.
- Background: PubMed 1550366Griffiths CE, Wang TS, Hamilton TA, Voorhees JJ, Ellis CN. A photonumeric scale for the assessment of cutaneous photodamage. Arch Dermatol. 1992 Mar;128(3):347-51.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly shared to protect participant privacy. Aggregate data supporting published findings are available from the sponsor upon reasonable request.
Related trials for Photoaging
RecruitingObservational study
Driving Time and Facial Skin Hydration Asymmetry in Florida Drivers
Skin Diseases, Photoaging
Recruiting
Study of RRS® HA Long Lasting for Improving Facial Wrinkles and Skin Quality
Photoaged Facial Skin, Photoaging
Active, not recruiting
Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin
Photoaging
Recruiting
SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants
Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation
RecruitingObservational study
Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1
Metastatic Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nana S Thompson, PhD, MPH principal investigator
SGS North America Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI-personalized skin longevity regimen in people with Photoaging and Skin Aging, run by MDalgorithms Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Expert-Graded Facial Photoaging Parameters (Modified Griffiths 10-Point Scale) (time frame: Baseline, Week 4 and Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07879833, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.